|
| 产品描述 |
| CWHM12 is a α(v) integrin inhibitor. CWHM 12 can suppress all 5 alpha V integrins. CWHM12 not only worked the same way to prevent fibrosis as the genetic deletion method, it also prevent the progression of existing fibrosis in the liver and lungs and reversed some of the damage caused by fibrosis to those organs. Delivering CWHM 12 or a similar small molecule directly into the lungs as an inhalant might offer a way to treat lung fibrosis. harmacological blockade of α(v)-containing integrins by a small molecule (CWHM 12) attenuated both liver and lung fibrosis, including in a therapeutic manner. |
| 化学结构 |
 |
| 化学名称 |
| (3S)-3-(3-bromo-5-(tert-butyl)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid |
| SMILES Code |
| OC1=CC(C(NCC(N[C@@H](CC(O)=O)C2=CC(Br)=CC(C(C)(C)C)=C2)=O)=O)=CC(NC3=NCC(O)CN3)=C1 |
| 基本信息 |
产品编号:XM313
产品名称:CWHM12
CAS#:1564286-55-0
分子式:C26H32BrN5O6
精确分子量:589.1536
分子量:590.475
纯度:>98%
|
| 物化性质 |
外观: 白色或类白色固体粉末
纯度: >98%
运输信息: 非危险化学品，适于常温或冰袋运输。
储存条件: 低温，干燥，避光。
溶解性: 溶于DMSO, 不溶于水
储存期限: 3 年 -20℃ 固体储存 2 年 -80℃ 溶液储存 |
该产品只供科研使用，不能给病人提供。
|
|
|
